Remove Clinical Trials Remove DEA Remove History Remove Patients
article thumbnail

Final Phase of MDMA Clinical Trials Shows Drug Is 90% Effective at Treating PTSD

SpeedWeed

A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. For this study, researchers recruited 90 patients suffering from severe, chronic PTSD. Image via. This promising new study is helmed by Rick Doblin, Ph.D.

article thumbnail

MAPS Organization Granted $12.9 Million to Study Cannabis and PTSD •

SpeedWeed

MAPS Makes History. This will be the second clinical trial to give cannabis medicine or placebos to participating military veterans, and according to the Chief Science Officer of the MAPS Public Benefit Corporation, Berra Yazar-Klosinki, PhD, the first trial was a great success. “We The study was funded with $2.2

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New Frontiers in the Law of Psychedelics

Cannabis Law Report

Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].

Law 105
article thumbnail

Veriheal’s Innovation in Cannabis Scholarship 2020 Winners

Veriheal

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Program between St. Bonaventure University and George Washington University School of Medicine. .

article thumbnail

Harvard Law Review: Patents on Psychedelics: The Next Legal Battlefront of Drug Development

Cannabis Law Report

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Patents on psychedelics raise unique concerns associated with their unusual qualities, history, and regulation. Trial of Psilocybin Versus Escitalopram for Depression , 384 NEW ENG. Mitchell et al.,

article thumbnail

New PTSD study finds cannabis safe, but not as effective as assumed

SpeedWeed

Preliminary results from a long-awaited study indicate that cannabis appears to be a safe and well-tolerated treatment for patients managing post-traumatic stress disorder (PTSD), although researchers did not find strong signals of effectiveness. They also wrote: The study sample included participants with a history of cannabis use.

article thumbnail

DEA Faces Lawsuit For Denying End of Life Patients the Right to Try Psychedelics Therapy

Veriheal

Plant medicines and concoctions made from them have been utilized throughout the history of cultures around the world. In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine. A Push by Patients.

Therapy 53